Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today’s available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.

This concise handbook provides oncologists and other healthcare providers with crucial updates in the field, including an updated review of the current understanding of the biology of the HER2 pathway, an overview of HER2-testing, and evidence-based discussions of available and emerging HER2-targeted treatment options. An essential clinical text for physicians that screen and treat patients with breast cancer and require an accessible, up-to-date survey of the dynamic treatment landscape.

The book you can trust to support you at every stage of your treatment - and beyond Winner of best 'Popular Medicine' book, BMA Medical Book Awards 2019 Professor Trisha Greenhalgh, an academic GP, and Dr Liz O’Riordan, a Consultant Breast Cancer Surgeon, are not only outstanding doctors, but they have also experienced breast cancer first-hand. The Complete Guide to Breast Cancer brings together all the knowledge they have gathered as patients and as doctors to give you and your family a trusted, thorough and up-to-date source of information. Designed to empower you during your breast cancer treatment, it covers: -Simple explanations of every breast cancer treatment -Coping with the emotional burden of breast cancer -Frank advice about sex and relationships -Staying healthy during and after treatment -Dealing with the fear of recurrence -Living with secondary breast cancer Packed full of all the things the authors wished they’d known when they were diagnosed, and tips on how to cope with surgery, radiotherapy, chemotherapy and beyond, this is the only book you need to read to guide you through your breast cancer diagnosis. 'A much needed guide which is both humane and based on robust evidence.' – Macmillan Cancer Support

Multidisciplinary in scope and fully up to date with the latest advances in medical oncology and more, Bland and Copeland's The Breast, 6th Edition, covers every clinically relevant aspect of the field: cancer, congenital abnormalities, hormones, reconstruction, anatomy and physiology, benign breast disease, and more. In a practical, easy-to-use format ideal for today's busy practitioners, this truly comprehensive resource is ideal for surgical oncologists, breast surgeons, general surgeons, medical oncologists, and others who need to stay informed of the latest innovations in this complex and fast-moving area. - Offers the most comprehensive, up-to-date information on the diagnosis and management of, and rehabilitation following, treatment for benign and malignant diseases of the breast. - Updates include an extensively updated oncoplastic section and extended medical and radiation oncology sections. - Delivers step-by-step clinical guidance highlighted by hundreds of superb illustrations that depict relevant anatomy and pathology, as well as medical and surgical procedures. - Reflects the collaborative nature of diagnosis and treatment among radiologists, pathologists, breast and plastic surgeons, radiation and medical oncologists, geneticists and other health care professionals who contribute to the management of patients with breast disease. - Includes access to procedural videos that provide expert visual guidance on how to execute key steps and techniques. - An eBook version is included with purchase. The eBook allows you to access all of the text, figures and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud.

This book provides the reader with up-to-date information on important advances in the understanding of breast cancer and innovative approaches to its management. Current and emerging perspectives on genetics, biology, and prevention are first discussed in depth, and individual sections are then devoted to pathology, imaging, oncological surgery, plastic and reconstructive surgery, medical oncology, and radiotherapy. In each case the focus is on the most recent progress and/or state of the art therapies and techniques. Further topics to receive detailed consideration include particular conditions requiring multidisciplinary approaches, the investigation of new drugs and immunological agents, lifestyle and psychological aspects, and biostatistics and informatics. The book will be an excellent reference for practitioners, interns and residents in medical oncology, oncologic surgery, radiotherapy, pathology, and human genetics, researchers, and advanced medical students.

Overcoming Cancers Resistant to HER-2 Antibodies provides general updated information on the resistance of various human cancers to anti-HER2 therapeutic antibodies. The book also discusses the description of various sensitizing agents that can reverse resistance when used in combination with anti-HER2 antibodies. There have been a lot of reports in which the treatment with anti-HER2 antibodies for various cancers has resulted in clinical responses; however, there have been also subsets of cancer patients who did not respond initially, and several responding patients developed resistance following treatments. Sections cover Lapatinib, Ganetespib, Paclitaxel, Celecoxib, Emantasine, Liposomal Doxorubicin, and Kinase Inhibitors.This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of the biomedical field interested in fighting cancer resistance to HER-2 antibodies. Provides a general summary of various sensitizing agents that can work effectively when used in combination with anti-HER2 antibodies to reverse resistance Offers potential underlying mechanisms by which cancer cells are either inherently resistant or become unresponsive to antibody treatment Discusses how to develop new targeted agents to underlie resistance in order to expand research on this field

In recent years it has become clear that breast cancer is not a single disease but rather that the term encompasses a number of molecularly distinct tumors arising from the epithelial cells of the breast. There is an urgent need to better understand these distinct subtypes and develop tailored diagnostic approaches and treatments appropriate to each. This book considers breast cancer from many novel and exciting perspectives. New insights into the basic biology of breast cancer are discussed together with high throughput approaches to molecular profiling. Innovative strategies for diagnosis and imaging are presented as well as emerging perspectives on breast cancer treatment. Each of the topics in this volume is addressed by respected experts in their fields and it is hoped that readers will be stimulated and challenged by the contents.

Adjuvant treatment is administered prior to or as follow up to surgical procedures for breast cancer. Proven success in using medical therapies allowing for breast conserving procedures or reducing risk of occurrence. Although there has been much progress towards a cure, including the introduction of new targeted therapies, metastasizing cancer remains highly incurable.

Breast cancer is a highly heterogeneous disease. Despite advances in early detection and treatment, breast cancer (BC) is the leading cause of cancer death in women worldwide. Heterogeneity negatively affects a patient’s prognosis, treatment sensitivity, and clinical outcome. In particular, the development of drug resistance mechanisms and the failure of anticancer drugs (initially or subsequently) could lie in the heterogeneity among BC patients and tumors. The major international guidelines have adopted an immunophenotypic sub-classification of BC to maximize patient eligibility for personalized therapy but do not take into account the extreme diversity existing between breast tumors (intratumor heterogeneity).